@article{b84cb77cc8a246d1b0d12c6d527f4071,
title = "Time to blur the blast boundaries",
keywords = "AML, MDS, acute myeloid leukemia, blast percentage, classification",
author = "DiNardo, {Courtney D.} and Guillermo Garcia-Manero and Kantarjian, {Hagop M.}",
note = "Funding Information: Courtney D. DiNardo is supported by a Leukemia & Lymphoma Society Scholar in Clinical Research Award and a V Foundation Lloyd Family Clinical Scholar Award. This research is supported in part by the MD Anderson Cancer Center Leukemia Specialized Program of Research Excellence grant (P50 CA100632). Funding Information: Courtney D. DiNardo reports research grants from AbbVie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Daiichi‐Sankyo, Immune‐Onc, and Loxo; honoraria from AbbVie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, Immune‐Onc, Novartis, Notable Labs, and Takeda; consulting fees from AbbVie, Agios, Immune‐Onc, Daiichi Sankyo, Celgene/BMS, Cleave, Invitae, GSK, and Servier; participation on a data safety monitoring board for Genmab; and stock or stock options in Notable Labs. Guillermo Garcia‐Manero reports research grants from Amphivena, Helsinn, Novartis, AbbVie, BMS, Astex, Onconova, H3 Biomedicine, and Merck and consulting fees from BMS, Astex, and Helsinn. Hagop M. Kantarjian reports research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi‐Sankyo, Immunogen, Jazz, Novartis, and Pfizer and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Pharmaceuticals, KAHR Medical, Ltd, NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada.",
year = "2022",
month = apr,
day = "15",
doi = "10.1002/cncr.34119",
language = "English (US)",
volume = "128",
pages = "1568--1570",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",
}